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Summary 
Background and research objectives 
Demographic and epidemiologic transitions have resulted in important shifts in population 
health patterns all over the world. The most advanced stages of these transitions can be found 
in high-income countries. Disease patterns have shifted from frequently fatal infectious short-
course diseases to chronic conditions associated with sometimes lifelong disabilities. These 
changes in population health patterns have led to the need for new indicators that are able to 
comprehensively quantify the impact of disease conditions on health. Summary measures of 
population health capture the overall impact of diseases by combining the effects of mortality 
and morbidity into a single indicator. Many summary measures exist, but there is one 
outstanding measure that is increasingly used throughout the world. Introduced in the first 
Global Burden of Disease study, the disability-adjusted life year (DALY) measure was used 
to quantify the burden of disease at global, regional, and national levels. Burden of disease 
analyses are increasingly performed to present the health of populations and to identify the 
major drivers of ill health, as well as the determinants that cause these decrements of health. 
Population health measures can also foster debate about priority-setting in the health-care 
sector and for health research. Despite the success of the burden of disease approach, there are 
still some substantial requirement, on the one hand, for adjustments of the DALY to better 
reflect the characteristics of infectious conditions and, on the other hand, for sub-national 
estimates of disease burden. This thesis takes up these two major objectives and introduces an 
appropriate methodology to measure the disease burden of infectious conditions, and also 
presents sub-national burden of disease estimates. 
Methodological concepts 
To meet the first objective of the thesis, the basic DALY methodology was tailored to reflect 
the characteristics of infectious diseases. Therefore, the perspective was changed from the 
disease endpoint to the pathogen perspective. Acute disease courses and future short- and 
long-term sequelae were accommodated by use of an outcome tree representing the natural 
history of an infectious disease. Incidence data, obtained from national surveillance systems 
and corrected for underestimation were use as the main input to the natural history models. In 
addition to the calculation of the current disease burden for hepatitis B virus, influenza virus, 
measles virus and salmonella spp. in Germany, projections of future burden were performed 
for the Netherlands, mainly focusing on the effects of population ageing and growth, as well 
as on the impact of intervention measures. 
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To meet the second objective of the thesis, SEYLL as a standardized measure of disease 
burden due to premature mortality was used to estimate the years of healthy life lost at sub-
national level for Hong Kong, SAR (China) and North Rhine-Westphalia (Germany). The 
focus was on testing the feasibility of using the SEYLL measure and identifying its potentials 
at a sub-national level. A further aim was to highlight the impact of social value choices on 
the SEYLL estimates. 
Results 
Introducing the incidence- and pathogen-based DALY approach, the highest disease burden in 
Germany (2005–2007) was estimated for infections with influenza virus (33,116 (95% UI: 
29,504–36,849) DALYs/year), followed by salmonella spp. (19,115 (95% UI: 14,803–
24,328) DALYs/year), hepatitis B virus (8,708 (95% UI: 7,335–10,163) DALYs/year) and 
measles virus (740 (95% UI: 413–1,066) DALYs/year). Infections with hepatitis B virus and 
salmonella spp. showed the highest burden related to sequelae with 98% and 56.6% of the 
overall burden, respectively. Predicting the disease burden from 2000 to 2030 in the 
Netherlands showed increases of disease burden from 1,196 (95% UI: 1,003–1328) DALYs to 
1,343 (95% UI: 1,194–1,493) DALYs for infections with hepatitis B and from 22,712 (95% 
UI 21,132–24,290) DALYs to 51,609 (48,212–55,198) DALYs for infections with influenza 
virus. The greatest reductions in the future disease burden due to hepatitis B infections were 
calculated for the scenario simulating the uptake of vaccination in all age groups (resulting in 
a per year decrease of incidence of 2%) with reductions in DALYs of 32% (compared to 
baseline). For influenza, the greatest reductions were simulated in the scenario with more 
effective age-targeted vaccination (resulting in a decrease of incidence of 5%) with reductions 
in DALYs of 45% (compared to baseline). 
Using the SEYLL as a measure of premature mortality at sub-national level resulted in 1.75 
million SEYLLs in North Rhine-Westphalia in 2005 and 524,707 SEYLLs in Hong Kong in 
2010. Non-communicable diseases accounted for the highest shares of SEYLLs, with 89.1% 
in North Rhine-Westphalia and 78.8% in Hong Kong. In comparison to prioritization by 
standard death counts, both studies highlighted self-inflicted injuries for males rising in 
priority from 13th to 8th rank in North Rhine-Westphalia and from 9th to 6th rank in Hong 
Kong, when using SEYLL as a measure of premature death. Scenario analysis identified that 
using different assumptions about social value choices decreased the SEYLLs by up to 51.6% 
(scenario I) and had a selective impact on the different disease groupings. Changing the 
standard life expectancy values to the ones observed in Hong Kong, the disease burden 
increased by 10.8%. 
vii 
 
Conclusions 
The results of the thesis showed that going beyond the one-size-fits-all solution as used in the 
global burden of disease study and drilling down estimates to a sub-national level can provide 
sound additional information on population health patterns. The use of the incidence- and 
pathogen-based DALY approach highlighted sequelae of infections with hepatitis B and 
salmonella spp. in particular as an important component of the overall disease burden. 
Furthermore, the approach also revealed the importance of including asymptomatic hepatitis 
B infections, because not considering these would have resulted in an underestimation of the 
disease burden by 80.1%. This is of major importance when prevention measures aim at 
avoiding the initial infection. In addition, the results of the thesis highlighted that this 
approach can also be used to predict future disease burden by including the impact of 
population and disease dynamics. The results presented in the thesis further fill existing data 
gaps for sub-national burden of disease estimates and introduce the SEYLL as a suitable 
measure for such assessments. The studies also demonstrated the advantage of using the 
SEYLL measure over standard measures of mortality, because considering age at death and 
estimating the loss of healthy years has considerable impact on disease priorities. Comparing 
the shares of group one and group two conditions highlights that the epidemiologic and 
demographic transitions in North Rhine-Westphalia were already far more advanced in 2005 
than they were in Hong Kong in 2010. 
Overall the thesis showed that the DALY and its components can serve as powerful indicators 
of population health, but there is a need to adjust the measures for specific settings. 
Furthermore, the thesis also emphasized the critical need for transparency when using the 
burden of disease approach and population health measures. Finally, it also accentuates the 
importance of increasing the quality of epidemiological estimates, because in the end 
summary measures are only as good as the epidemiological input data. 
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1. Introduction 
During the last two decades, health-care demands and costs have increased dramatically but 
public spending on health care has remained restricted, making budget constraints and health-
care cuts inevitable. As a result, due to the observed global financial downturn, economic and 
political areas, as well as research, face an increasing demand for reasonable prioritization 
approaches to allocate the scarce resources. Prioritization processes, especially in health 
policy-making, are very complex and require not only financial but also ethical, legal and 
many other aspects to be taken into account [1-4]. Setting priorities in the health sector always 
involves trading off different diseases, risks and their impacts on health against each other, 
allowing us to decide where the spending of resources might result in the highest pay-offs in 
terms of health benefits. These can be considered as pay-offs for individuals, increasing their 
health status, or for a whole population, resulting in health benefits for a group of people, a 
geographical area or country. Taking the population perspective, it is of great value to identify 
the health status and related health/disease patterns of populations along with the major 
drivers of ill health [2]. Traditionally, the health status of populations was measured by 
classical (aggregated) epidemiological surrogate parameters such as overall or cause-specific 
mortality, mortality of children aged less than five years (under-5-child-mortality) or 
derivative measures such as life expectancy that are based on mortality trends observed in the 
past [2, 5]. The effects of diseases on health, however, go far beyond death and include a wide 
range of impacts. In the era of emerging trends observed as demographic and epidemiologic 
transitions, it became evident that indicators of mortality are of limited use in many settings 
because they miss important information which is necessary in order to make a 
comprehensive and informed choice [5]. 
During the phase of epidemiologic transition, the disease patterns (e.g. in a country or region) 
are shifting from infectious, frequently fatal conditions (e.g. diarrheal diseases or respiratory 
tract infections) to chronic, primarily non-fatal conditions (e.g. diabetes, cardiovascular 
diseases or neuropsychiatric disorders) that may often last for decades and incur substantial 
health expenditure [6-8]. In addition, it became evident, that many people do not suffer from 
only a single disease but have many co-morbidities, making assessments of population health 
and predictions about disease progression difficult [6, 9]. The demographic change is 
characterized by a change from high to low fertility- and mortality rates and increased life 
expectancy. These changes result in transformations of the population structure, with an 
increasing proportion of elderly and decreasing proportions of young segments [10, 11]. Both 
transition concepts have resulted in remarkable changes in health/disease patterns, especially 
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in developed, high-income countries, and have required the introduction of adequate health 
indicators that are able to capture the mortality, as well as the morbidity effects of diseases 
and injuries [12]. Despite the remarkable shifts in health patterns of high-income countries 
towards chronic conditions, infectious diseases still play an important role as new infections 
are emerging, old infections are reemerging and links between infectious agents and chronic 
conditions are becoming evident [13-16]. All these different processes pose a demand for 
population health measures that are sensitive to the different characteristics of diseases and 
allow a comprehensive and comparable view of health patterns. 
The increasing importance of diseases that do not primarily lead to death but impact on 
quality of life has highlighted the need for measures that are able to cover the different 
dimensions of population health [2]. To accommodate diseases with different characteristics, 
summary measures of population health (SMPH) were developed to comprehensively 
measure the impact of different health-reducing conditions. Summary measures have a long 
history [17], and many types have been developed and used over the last decades [2, 18, 19], 
but one of the most prominent and frequently used measures is the Disability-Adjusted Life 
Years (DALY), a measure of lost healthy years that was introduced during the late 1980s [20-
22]. The DALYs are used in burden of disease (BoD) studies and quantify the health status of 
populations. Estimating the disease burden in a population is of major importance in 
identifying the key drivers that contribute most to the loss of health. BoD analyses allow a 
comprehensive, comparable and internally consistent assessment of population health. By 
giving researches the opportunity to compare heterogeneous conditions, analyses of the 
disease burden can provide effective and evidence-based supplementary information for 
priority-setting purposes in the health sector. In contrast to classical health monitoring 
indicators, such as incidence, prevalence and mortality, BoD analyses rely on the combination 
of epidemiological information into one single metric. The quantification of health losses into 
a single, standardized measurement unit has the advantages that: a) the different 
characteristics of heterogeneous conditions can be comprehensively taken into account and b) 
ad hoc comparisons between conditions and countries and over time are possible. 
The development of the BoD methodology and the dissemination of the results were mainly 
driven by the Global Burden of Disease (GBD) studies firstly initiated by the World Health 
Organization (WHO) in cooperation with the World Bank and the Harvard School of Public 
Health [20, 23]. Despite the tremendous benefits of the GBD estimates, the methods 
employed in the studies have received considerable criticism from the scientific community 
[24-27]. Much of the criticism was related to methodological choices and inputs (e.g. time-
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discounting, age-weighting or disability weights) for the calculation of the DALY. However, 
the quality of the epidemiological input data that form the backbone of the DALY was not 
much of an issue. Furthermore, in line with the aim of the GBD study, to provide global 
estimates, the results are limited to the country level. However, having an average (mean) loss 
of healthy life years for a whole country might be misleading due to existing regional, social 
or cultural health inequalities. In addition, it is also questionable whether the one-size-fits-all 
methodological solution is fully appropriate for widely diverse conditions (e.g. communicable 
diseases, non-communicable conditions and injuries) and whether approaches more tailored 
towards the specific characteristics of diseases might result in more accurate estimates. 
This dissertation takes up two relevant challenges and focuses on: a) the adjustment of the 
BoD methodology to meet the characteristics of infectious diseases and b) the application of 
BoD analyses at a sub-national level. 
The thesis first provides an overview of the theoretical frameworks of population health and 
BoD and focuses on key methodological concepts of the BoD methodology, highlighting 
SMPH and the DALY as the core metric. This part of the dissertation will elucidate potentials 
and methodological limitations, as well as shortcomings regarding the limited regional 
differentiation of the currently available BoD estimates and the need for adjustments when 
estimating the disease burden of infectious pathogens. The subsequent sections will provide 
the methodological specifications of the approaches used in the analyses, introducing the 
methods developed for the Burden of Communicable Diseases in Europe (BCoDE) Project 
and the Standard Expected Years of Life Lost (SEYLL) as a standardized measure of 
premature mortality. The application of these concepts will be illustrated by BoD studies in 
Germany (BCoDE), and SEYLL studies in Hong Kong and North Rhine-Westphalia (NRW). 
The results of the studies and the related implications for the further development of the BoD 
framework will be elaborated and discussed in the final chapters of the thesis.  
The six publications relevant to the dissertation are the following: 
- “The Pathogen- and Incidence-Based DALY Approach: An Appropriate Methodology for Estimating 
the Burden of Infectious Diseases” – an article describing the methodological specifications of the 
BCoDE Project (published in PLOS ONE) [28]. 
- “Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of 
methods.” – an article investigating the methods that are currently used to quantify underestimation in 
infectious disease surveillance data (published in BMC Public Health) [29]. 
- “The disease burden of hepatitis B, influenza, measles and salmonellosis in Germany: first results of the 
Burden of Communicable Diseases in Europe Study” – an article presenting an application of the 
developed methodology in Germany (published in Epidemiology and Infection) [30]. 
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- “The impact of demographic change on the estimated future burden of infectious diseases: examples 
from hepatitis B and seasonal influenza in the Netherlands” – an article focusing on a further extension 
of the BCoDE methodology (published in BMC Public Health) [31]. 
- “Measuring the burden of disease due to premature mortality using Standard Expected Years of Life 
Lost (SEYLL) in North Rhine-Westphalia, a Federal State of Germany, in 2005” – an article focusing 
on a sub-national BoD analysis in Germany (published in Journal of Public Health) [32]. 
-  “Quantifying the burden of disease due to premature mortality in Hong Kong using standard expected 
years of life lost” – an article investigating the feasibility of applying standardized BoD measures at a 
sub-national level and the effects of social value choices on estimates of disease burden (published in 
BMC Public Health) [33]. 
2. Theoretical constructs of population health and burden of disease 
The description of diseases and their impact on health has a long history and in general there 
are two distinctly different perspectives to be taken when health and disease are the focus of 
investigations. Traditionally when considering the impact of diseases and injuries on human 
health, the first perspective is the individual one, where the aim is to detect, diagnose and treat 
a disease and if possible heal a single individual of his individual disease-specific symptoms. 
Since the early efforts of John Snow, the first epidemiologist, who investigated a cholera 
outbreak in London, another important perspective has also been highlighted [34]. Focusing 
on the health situation of a group of individuals and how a single disease or set of diseases are 
distributed among different population groups taking the population perspective is a necessary 
step [35]. Describing the health of a population not only allows researchers to present the 
health status of this population but also to identify the key drivers contributing to ill health 
[36]. Population based health information is necessary to identify the determinants that incur a 
substantial disease burden and influence health patterns [12, 37, 38]. This information can be 
used in a descriptive manner to monitor trends and developments of diseases in a population 
but also in an analytical manner, by which health determinants and their contribution to 
population health can be analyzed [39]. Population health is a relatively new terminology and 
a final definition is not yet fully agreed upon [40]. However, Kindig stated that population 
health describes “the health outcomes of a group of individuals, including the distribution of 
such outcomes within the group” ([37] p. 381). Figure 1 presents the framework of population 
health and identifies three major branches and their interactions that are of interest for 
population health – 1) health outcomes and their distribution in a population, 2) patterns of 
health determinants over the life-course and 3) policies and interventions at the individual and 
social levels that influence health determinants and the processes by which these factors 
impact on health [37]. Kindig and Stoddart refer to Dunn and Hayes who describe population 
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health as the health status of a defined population, “[…] as measured by health status 
indicators and as influenced by social, economic and physical environments, personal health 
practices, individual capacity and coping skills, human biology, early childhood development, 
and health services” ([41] p. S7). Population health can be described as an umbrella concept 
encompassing a wide range of health aspects including health determinants, and thus can 
provide a broader view and more integrated concepts [40]. Public health, in its narrow 
definition, has evolved into a very specific field of research with many specialized areas, 
which can be broken down into many different sub-disciplines, covered by different 
organizational institutions with different responsibilities in a society [40]. All these sub-
disciplines introduce specific measures to improve the health status of populations in different 
sectors of social life. To shed additional light on the joint effects of these measures, 
population health as a discipline aims to combine the evidence from different fields of health 
research to provide a full overview of overall health patterns and the effects of intervention 
and prevention options on a certain population [37]. 
Using the population health perspective allows researchers to identify critical aspects of the 
health situation of a population and thus enables decision-makers to include this important 
information when allocating scarce resources in the health sector. Decisions about resources 
are inevitable and the rationale for these decisions is not always based on scientific evidence; 
in the worst case, it can be guided by political issues or the gut feelings of experts. To avoid 
biased decisions, it is important to reach decisions from transparent information. Many efforts 
have been made in the field of evidence based public health to increase the use of scientific 
evidence to inform political decisions [42, 43]. Solid information about the health status of a 
population presented in a comprehensive and communicable way is one of the factors often 
lacking when priority-setting processes are taking place. These processes can be guided by 
various epidemiological indicators of population health. When describing the effects of 
disease and injuries, these indicators allow a simplified distinction between two effects – 
morbidity and mortality. 
Measuring the effects of mortality in general is more straightforward because mortality is a 
dichotomous measure of being alive or dead [44]. To capture mortality effects on population 
health, it is important to know how many people are dying overall (overall mortality) in a 
population in order to have the consistent death envelope and also to be able to identify the 
causes people are dying from (cause specific mortality).  
Morbidity effects are far more complex and pose the need for a wide array of different 
indicators to capture the impact of non-fatal disease and injury conditions. They range from 
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data obtained from (ideally representative) community-based surveys to nationwide 
surveillance systems (e.g. mandatory infectious disease surveillance). From the population 
health perspective indicators of disease occurrence, such as incidence: the number of new 
cases in a population over a fixed time period, and prevalence: the number of current cases at 
a certain point in time (point-prevalence) or over a set time-frame (e.g. three-month 
prevalence), are frequently used measures of morbidity in a population. Information about 
disease frequency is important but limited because these indicators do not capture the severity 
of a condition and do not inform us about the level of health-related quality of life (HRQoL). 
This information is necessary, however, to allow comparisons of different disease outcomes. 
HRQoL can describe both subjective and objective judgments about the impact of health 
reducing-conditions on different dimensions of human health. Thus, in order to capture and 
quantify the effects of morbidity it is insufficient to only enumerate the number of incident or 
prevalent cases and including the impact of a condition on health is inevitable. 
When prioritizing diseases with heterogeneous characteristics, regarding their impact on 
population health, focusing on only one of these two epidemiological indicators might result 
in misleading priorities because a condition might score high on the level of morbidity but 
low on the level of mortality. If this condition is then compared with another condition that 
scores low on both levels, and only the mortality indicator is considered, both conditions 
might get the same priority, even though the first condition scores higher on the morbidity 
level [2]. For instance, one can take the example of two conditions, namely depression and 
infertility. Depression scores high in morbidity and low in mortality. Infertility might score 
much lower than depression on the level of morbidity but, like depression, would not result in 
any deaths. Drawing comparisons from the mortality perspective would result in the same 
impact on health, but if morbidity were also considered, this would result in significant 
differences and probably a higher priority would be given to depression. 
Comparing broad sets of conditions, such as communicable diseases, non-communicable 
conditions and injuries, thus poses the need for a framework that enables researchers to 
combine the available epidemiological information into a single measurement unit. Therefore, 
the BoD framework was developed for the first GBD study [20]. The GBD study 
accommodated a set of distinctly different disease and injury conditions and using single 
epidemiological indicators was therefore insufficient. The BoD framework introduced for the 
first time a standardized, conceptual and methodological concept for capturing the overall 
levels of population health and the causes of loss of health [45]. In addition to facilitating the 
comparison of various health-reducing conditions, this standardized framework also enabled 
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comparisons across countries and regions, and over time. Furthermore, as health data are not 
distributed equally across or within populations the BoD framework also provided a set of 
techniques to supplement missing data and to fill the existing data gaps [45]. If data are not 
available for a certain population group or health condition, it is often wrongly concluded that 
where there is no data there is accordingly also no burden. This is frequently wrong, because 
data for the most vulnerable populations is often lacking, making improvements in population 
health data a major imperative [12]. The BoD approach relies on measures of population 
health that, according to Parrish, can be subdivided into measures of a) mortality, life 
expectancy and premature death b) health function and subjective well-being c) the 
distribution of health in a population and d) summary measures of population health [46]. 
2.1. Summary measures of population health 
The demand for high-quality data in health care is increasing because health data can serve as 
a powerful instrument for different stakeholders in health care but also in other adjacent 
sectors [2, 12, 47, 48]. The increasing quantity and quality of health data has resulted in a 
massive overload of often complex indicators making informed decision-making a difficult 
task [2, 48]. 
The attempt to condense indicators of population health into one single measurement unit has 
a long history [17, 49-51] and many SMPHs have been developed and used to pursue various 
objectives and in many settings [18]. All summary measures have the common aim of 
presenting the health status of a population as one quantity, making heterogeneous conditions 
comparable. As disease patterns have changed over the last few decades, the development of 
SMPHs was a necessary step to accommodate conditions that cause non-fatal decrements in 
health but not mortality [2]. From the public health perspective, SMPHs present a powerful 
tool of descriptive epidemiology because they capture the health situation of a population and 
are able to identify key drivers of health decrements and conditions, thus increasing the 
potential for reductions in the disease burden. Where this information is available, measures 
of intervention and prevention that have an impact at the population level can be guided more 
thoroughly as compared to the use of uni-dimensional indicators. Furthermore, these 
quantifications of health status can lead to reasonable comparisons between different 
populations (e.g. countries) and help to evaluate health-system performance overall [52]. This 
enables the furthering of debate about the important questions of why health patterns differ 
between populations, to what extent health systems can be held responsible for these 
differences, and which prevention and intervention measures have led, and in future may lead, 
to the best pay-offs [2]. SMPH can also be a general indicator of the current stage of 
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development of a country and can also reflect innate societal and cultural differences. As a 
standardized measure of health SMPH further allows the monitoring of population health over 
time and, thus, the tracking of overall health trends or changes in health patterns after 
intervention measures. This retrospective view is of major importance as it identifies 
achievements, challenges and unfinished agendas in health research. A further benefit of 
using SMPH arises from the unequal distribution of health, not only between populations but 
especially within populations or population groups. SMPH can be used at different population 
levels (global, regional, national and sub-national) to help in identifying inequalities in 
population health and the possible reasons (e.g. risk factors, socio-economic determinants) for 
this unequal distribution [32, 53-56]. This might stimulate national and international debates, 
introducing normative aspects into SMPH. With the characteristics described, SMPH is a 
useful tool help in setting priorities, on the one hand, for resource allocation in terms of 
prevention, intervention and care, and on the other hand, in research and development. 
Various types of SMPH exist and the number of newly developed indicators has been 
continuously increasing over the last few decades. From a general and technical point of view, 
SMPH can be broadly subdivided into two kinds of “families” – “health expectancies” (HEs) 
and “health gaps” (HGs). As indicated by their names, HEs measure positive quantities of 
health and HGs quantify decrements. Figure 2 describes the concepts of these families in a 
simplified framework of a hypothetical cohort and its survival [18]. The green line indicates 
the general survival of the hypothetical cohort along a time span of 100 years and enumerates 
the percentage of people in this cohort surviving at each age. Some of the people may die 
while they are completely healthy, e.g. due to a car accident, some may suffer a short-course 
infectious disease before death, and another segment of the population may suffer long-lasting 
chronic diseases before death. To tease these differences apart, in the first step the black curve 
indicates the proportion of people surviving at each age without any restrictions on their 
health (full or ideal health). The area/integral (A) under the optimal-health-survivor curve can 
be described as the life expectancy without any decrements of health. Area B presents the 
time lived in health states that are less than ideal. The sum of areas A and B represents the 
overall life expectancy. Area B can also be differentiated into areas describing a gradient of 
health status with a part of the area B (f (B)) still counting as healthy and another part 
counting as non-healthy years. Combining areas A and the “healthy” part of area B results in 
the number of healthy years expected to be lived by the hypothetical cohort (healthy life 
expectancy) [18].In contrast, an HG measures the loss of health (healthy years) according to a 
selected norm. The normative health goal, as represented by the vertical line at age 100 in 
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Figure 2, can be an arbitrary limit to the length of life (100 years in the selected example) or 
any other chosen norm that can be selected according to the research objectives. This limit is 
then used to capture the difference between this normative health goal and the observed 
survival of the population. Therefore, area C represents the loss of health (healthy years) due 
to the effects of mortality.  
As SMPH is intended to measure the full spectrum of disease impact on health, adding the 
part of area B that represents ill health (g (B)) to area C allows us to include both the health 
losses due to time lived in a state of less than full health and time lost due to dying before 
having reached the normative health goal [18]. Even though the theoretical framework of 
SMPH describes HGs and HEs as complementary, there are two important aspects that need 
to be considered. SMPH in general can take an absolute, and thus age-dependent, or an age-
independent form. HEs in general are independent of the age structure and do not allow an 
additive decomposition. HGs are often expressed as absolute values and are thus dependent 
on the age structure of the underlying population. In contrast to HEs, HGs enable additive 
decomposition. For instance, the lost years in different age groups within a population would 
add up to the envelope of overall lost years. For HE measures, adding up the life-expectancy 
values of the different age groups would not yield meaningful results [57]. Several variants of 
both health expectancy [58-62] and health gap [63] measures have been developed but there is 
one outstanding measure used in many BoD analyses – the disability-adjusted life year. 
2.2. Disability-adjusted life years 
One of the most prominent members of the health-gap family is the DALY measure. The 
DALY was developed as the core indicator for the first GBD study [20, 22] and was 
subsequently used in ongoing updates of the GBD estimates [64-70], in national (e.g. [71-
74]), and some sub-national BoD studies (e.g. [53, 56, 75]) and also in condition- and risk-
specific assessments (e.g. [76-79]). The DALY as it was introduced in the first GBD study is 
an SMPH that captures the effects of both mortality and non-fatal health outcomes. In order 
for these effects to be combined, the unit to measure the disease burden was chosen to be time 
(years) and, as a health gap-measure, the loss of time. Because they use time as the common 
outcome currency, the DALY estimates have the advantage of being a comprehensible and 
illustrative way to describe population health. 
 
“The DALY concept has the potential to revolutionize the way in which we measure the impact 
of disease, how we choose interventions, and how we track the success or failure of our 
intervention. […]”( [80] p. 1705).  
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This quote describes the potential objectives of the DALY. It measures the impact of disease 
on population health, and the resulting priority rankings can guide resource-allocation 
processes towards reasonable intervention measures, which finally can also be evaluated by 
tracking the DALY through time. Despite its potential and benefits, the DALY has been 
subjected to a lot of criticism by scientific community. It was not argued that the DALY, as a 
construct, was inadequate to measure population health, but rather, the detailed assumptions 
and decisions that were agreed upon for the first GBD study were criticized [24-27]. There 
were four major points of criticism raised.  
The first point was the standard life expectancy that set female life expectancy at 82.5 and 
male life expectancy at 80 years. The female life expectancy was based upon the highest 
observed value, which was at that time found in Japanese women [22]. The two and a half 
year difference between the life expectancies of women and men was not consistent with the 
truly observed gender gap, which is related both to biological differences and, to a large 
extent, to life-style-related factors, causing a lower life expectancy in men. It was argued that 
the gap chosen for the GBD study should only consider the biological differences between 
males and females and should not include life-style-related factors [22]. This artificial 
increase in male life expectancy might overestimate the disease burden of men and thus might 
result in misleading priorities [81]. Furthermore, it was also argued that using a global 
standard might be adequate for global assessments but, for national-based priority setting 
using a national or even sub-national life expectancy might be more appropriate. 
The second and third points relate to the concepts of age-weighting and discounting, two 
approaches which allow different weighting of years: a) lived at different ages and b) in the 
future. Both concepts highlight the economic perspective and are optional social value choices 
that were included in the first GBD study but have been partly disregarded in many 
subsequent studies [22]. Age-weighting is a concept that gives different weights to years lived 
at different ages and thus refers to the concept of human capital and the theory of social roles 
[22]. Years lived in age groups of people with the most valuable roles for a society, such as 
persons of productive age, received higher weights than the remaining younger and older age 
groups. The concept of discounting relates to years lost in the future, which in general 
economic terms are discounted because the value of goods – as shown in population-based 
trials – is considered to be higher at present than in the future, indicating a discounting of 
future goods. 
The fourth point is related to the quantification of the impact of non-fatal conditions on 
health. In the DALY measure, the severity of a condition is measured by disability weights 
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that describe the impact of diseases and injuries on health using a numerical value anchored 
on a scale from zero, representing full health, to one, a health state comparable to death. 
These disability weights form a bridge between mortality and non-fatal health outcomes. All 
conditions considered for the first GBD study were valued by a group of health professionals 
using the person trade-off technique [20]. The derived disability weights received a lot of 
criticism which, on the one hand, was guided by the argument that, when allocating public 
goods, the preferences of the public should be taken into account and, on the other hand, by 
the fact that a multi-dimensional construct such as health has been condensed to a uni-
dimensional scale ranging from zero to one. Another aspect of criticism was that it was 
assumed that the weights assessed by a group of experts would count equally throughout the 
world without any country- or cultural-specific variation in the perception of disease severity 
or the impact of diseases and injuries on human health [82]. Despite these criticisms, the first 
set of disability weights as assessed for the first GBD study was subsequently used in several 
BoD studies due to reasons of comparability but also due to the fact that no other consistent, 
comprehensive and comparable set of weights was available until the update of the GBD 
study [82]. When calculating the DALY it is very important to provide a transparent overview 
of all the assumptions that were made because altering the social value choices might have a 
considerable impact on the priorities arising from the DALY estimates. 
The DALY as introduced by the first GBD study is a composite health measure consisting of 
two sub-measures – the years of life lost due to premature mortality (YLL) and the years lived 
with disability (YLD). The technical basis for the calculation of the DALY is shown in Box 1. 
The DALY was used in many different variants and settings, but the GBD study, its updates 
and the complete revision of the GBD are the landmark studies promoting the use of SMPH, 
and especially the DALY, as the core measure of the GBD [20, 69, 70, 83]. 
3. Current state of burden of disease research 
Before the first GBD study [20, 23] no internally consistent set of data was available to 
describe the health status of the world’s population. Estimates of overall deaths and cause-
specific death rates were not consistent and summing all cause-specific death rates resulted in 
more deaths than were actually observed and counted. Thus, health data were highly 
fragmented and an ambiguous description based on cause-specific estimates resulted in 
skewed priorities. Therefore, the initiators of the GBD study placed major emphasis on 
constructing a framework that combined all the available epidemiological information and 
produced internally consistent estimates [20]. This is only possible if all the inconsistencies 
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between data sources are identified and resolved [84]. In their first GBD study, Murray and 
Lopez came up with an initial comparable view of the world’s health status and for the first 
time information on diseases with heterogeneous characteristics was gathered together and 
conditions were presented in a priority ranking, identifying the major drivers of ill health. It 
was evident that the inclusion of the impact of non-fatal health outcomes meant that many 
conditions, such as major depressive disorders that primarily contribute to YLDs, would be 
left under-prioritized if e.g. the focus was set towards cause of death statistics, or mortality 
indicators in general. The first set of DALY estimates was presented for eight world regions 
[20] and subsequent updates introduced country-specific estimates. The GBD study also 
introduced a specific classification system which in general is related to the ICD system but is 
more instrumental for presenting the results of population health patterns1.  
For the current update of the GBD study, conducted by the Institute for Health Metrics and 
Evaluation (IHME), the complete methodology and especially the data inputs were 
reconsidered and the new methodology was applied to estimate the global disease burden in 
2010. In addition the new concepts were also applied for the full time period between 1990 
and 2010 to generate a fully comparable time series of DALY estimates [70]. Furthermore, all 
estimates provided by the GBD 2010 study consider uncertainty, both in the available 
epidemiological data and stemming from the modeling procedures used. This increases the 
transparency and may help to identify conditions where uncertainty is high, indicating a rather 
low quality or quantity of available health data. 
Even though the estimates of the GBD studies are of major importance in providing an 
overview of global health patterns, all the estimates presented are average values for a super-
region, region or country. Since data quantity and quality, especially in high-income 
countries, are increasingly available in a higher spatial resolution it is a necessary step to drill 
down the assessments to small-scale analyses of the disease burden. 
3.1. Sub-national burden of disease studies 
Research on health inequality has shown that health, and burden of disease as the equivalent, 
are not equally distributed either between or within countries [85]. This is strongly related to 
the determinants of health, which operate at different dimensions of human health (e.g. 
                                                 
1 All causes from the ICD classification system can be redistributed to the entities of the GBD classification. The 
GBD classification system is structured into several levels of detail. At the first and broadest level, conditions are 
split into group one, two and three conditions. Group one includes communicable diseases, and maternal, 
neonatal, and nutritional disorders. Group two encompasses non-communicable conditions and group three 
represents injuries. At the next level all conditions are split into by 21 main cause groups (e.g. malignant 
neoplasms or mental and behavioral disorders). The following levels show further details of single-disease 
conditions such as HIV/AIDS, liver cancer, or road traffic injuries. This classification system allows a very 
intuitive way of presenting health patterns. 
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physical or mental wellbeing) and also at different population levels (e.g. country, district or 
population groups that have common characteristics) [38]. Therefore, the estimates given by 
the GBD study can only provide a limited view of population health and its distribution 
among heterogeneous population sub-groups. A necessary step is to differentiate the overall 
disease burden estimates into smaller spatial levels or specific subpopulations (e.g. indigenous 
population [54]). With the assessment of disease burden at a sub-national level, priority-
setting processes become more meaningful and intervention and prevention strategies can be 
tailored more carefully towards the identified needs. Few assessments have focused on the 
application of the disease burden at a sub-national level and more studies are generally needed 
[53, 56, 75, 86-89]. Overall, most studies have aimed to apply the burden of disease methods 
to small-scale analysis, e.g. at the level of a Swiss canton [75], boroughs in London [53] or for 
specific population groups, such as the employees of General Motors [88]. All these studies 
have in common that they use the mortality component, YLL, as the basis to estimate the 
DALY. Having mortality data at hand and being short of local estimates for morbidity 
surrogate parameters, the YLDs were estimated by using a YLL/YLD ratio from available 
national or regional estimates. For these studies, the YLL/YLD ratios from regions/countries 
were assumed to be akin to the ones observed locally. This might hold true for many 
conditions but can also lead to significant differences mainly related to potential regional 
differences in e.g. access to health care or socio-economic status. Depending on availability 
and quality, average YLL/YLD-ratios might under- or overestimate the disease burden due to 
YLD and thus have considerable impact on the estimated DALYs. Due to the lack of 
morbidity data, a few assessments have also focused on estimating single components of the 
DALY, namely the YLL, or more specifically SEYLL, which are a standardized measure of 
premature mortality [90-93]. Compared to data on morbidity, mortality data is collected more 
comprehensively and is available for smaller spatial units. SEYLL offer a distinct perspective 
on mortality patterns and are of value in identifying the drivers of premature death causing 
losses of healthy life years. Overall, sub-national estimates of the disease burden are widely 
lacking throughout the world. Even in high-income and data-rich countries, information on 
sub-national population health patterns is scarce. This thesis takes up the need for sub-
national assessments of the disease burden in Germany and China and aims at reduce this 
research gap. 
3.2. Burden of infectious diseases 
Estimates from the GBD studies clearly highlight that infectious diseases cause major 
decrements of population health in low-income countries [69, 70]. Conditions such as 
14 
 
HIV/AIDS, malaria, lower respiratory infections, and diarrheal diseases cause deaths and 
reductions to health and despite the ongoing efforts to fight those diseases, it still seems to be 
an unfinished agenda. Results from the GBD 2010 study showed that, even though successful 
intervention and prevention strategies led to a decrease in the disease burden from 1990 to 
2010 of 45% for lower respiratory infections and 52% for diarrheal diseases, these two 
conditions are still the leading causes of DALYs in the developing world [94]. For HIV, the 
trends indicated an overall increase of 389% from 1990 to 2010 in developing countries; 
however, this masks the fact that rates have declined since about 2005 from 1,768 
DALYs/100,000 to 1,474 DALYs/100,000 in 2010 [95]. The same holds true for malaria, 
where overall trends from 1990 to 2010 showed increases in the malaria burden of 18%, but a 
decreasing trend in rates since 2005 from 1,934 DALYs/100,000 to 1,476 DALYs/100,000 
[95].  
In developed countries, infectious diseases are considered to be under good control and from a 
population health perspective prevention and control measures for non-communicable chronic 
diseases (NCDs) currently receive higher priority. According to the GBD estimates for 2010, 
most of the DALYs in the developed world are due to NCDs, which have reached about 83% 
of the overall burden [95]. The low burden of infectious diseases can, however, be explained 
by previous investments in the improvement of hygiene standards and the development and 
introduction of highly effective treatment and preventive measures, such as vaccination. Many 
of those measures are operating at the population level and rigorous vaccination regimes have 
successfully reduced the disease burden due to many infections conditions such as measles, 
whooping cough, and tetanus [94]. Despite the successful battle against many infectious 
diseases, observed especially in most Western European countries [96], newly emerging and 
re-emerging infectious diseases pose threats to the health of populations [97-100]. Pandemics 
such as that introduced by the severe acute respiratory syndrome (SARS) in 2002 [101] or the 
H1N1 pandemic influenza in 2009 [102] have hit even the developed world and caused a 
considerable disease burden, with 8,096 cases and 774 deaths for SARS and 94,512 cases and 
429 deaths for H1N1 observed globally during the outbreaks [103, 104]. Such outbreaks are 
not predictable as they are associated with new or genetically mutated strains for which 
effective treatment options need to be sought to prevent further spread. In contrast to newly 
emerging infectious conditions, re-emerging diseases seemed to be under control or have even 
been largely eradicated from the European continent. Different societal changes however, 
have led, and probably will again lead, to the re-emergence of such conditions. Tuberculosis 
is an important example and presents as a major health problem in Eastern European and 
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former Soviet countries. During and after the breakdown of the Soviet Union, health-care 
services were not able to sustain successful treatment of tuberculosis patients. The incidence, 
and accordingly the burden, of tuberculosis and co-infections of tuberculosis with HIV are on 
the rise and not only pose a threat to the population of origin but might also have an impact on 
neighboring countries due to the effects of migration [105]. In particular, increasing rates of 
drug-resistant strains, due to inadequate treatment of tuberculosis patients, are a major threat 
to population health in the former Soviet countries [106]. Another important example of a re-
emerging infectious disease is measles, where effective vaccination is available and the 
disease is fully preventable. Nevertheless, many European countries face outbreaks of measles 
mainly related to under-vaccinated pockets within the country. The reasons for the low 
vaccination coverage vary widely but in many cases can be related to anthroposophic or 
religious beliefs leading to measles outbreaks, as recently observed in the “bible-belt” of the 
Netherlands [107].  
Despite well-established surveillance systems in most of the high-income countries situated in 
the European area, comprehensive and comparable estimates of the disease burden are 
lacking. Even though prioritization processes for infectious conditions are increasingly being 
introduced [108], there is a missing link to the priority-setting mechanisms used for non-
infectious conditions. Burden of disease estimates as measured by the DALY are only 
provided by the GBD study and national estimates for the infectious disease burden are 
lacking or only give estimates for certain conditions, condition groups, years or a given 
outbreak of an infectious disease (e.g. chikungunya [76] pandemic influenza [77] or 
foodborne pathogens [109, 110]). For infectious diseases, it is generally of increased interest 
to have disease-burden estimates for specific pathogens. Such estimates, which are of 
particular importance from the public health perspective, are generally lacking, or only 
provide a fragmented view of the overall disease burden of infectious diseases. It has been 
identified that, especially for Germany, BoD estimates are generally lacking and that there is a 
need for pathogen-specific estimates. The pathogen-specific approach offers new perspectives 
for BoD research, especially for public-health interventions aimed at preventing new 
infections. 
3.3. Research needs for methodological refinements and regional differentiation 
From the currently available estimates of disease burden, three major challenges were 
identified and these three aspects form the backbone of the research conducted for this 
dissertation. 
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The first point relates to the one-size-fits-all solution of the BoD approach as currently used 
for the GBD study and other assessments. As the aim of the GBD study was to accommodate 
a large set of heterogeneous disease and injury conditions and the objective was to generate a 
global overview, a common framework was developed. This forced compromises, which had 
a selective impact on the sensitivity of the framework to adequately capture specific aspects 
of diseases. Unique characteristics of particular diseases might not be considered adequately, 
resulting in skewed estimates and, consequently, in misguided priorities. When transferring 
the approach to specific settings, probable adjustments seem to be worthwhile and necessary, 
to increase the suitability of the methods used. Here, infectious diseases in particular, their 
dynamics and complicated natural histories, with acute illnesses and short- as well as long-
term consequences resulting from the initial infection, deserve special attention. In particular, 
if the aim of the study is to set priorities within a group of conditions, such as infectious 
diseases, a framework can be tailored specifically towards the demands of this set of 
conditions, thus achieving more robust estimates. Current estimates of the infectious disease 
burden either do not include the full spectrum of infectious disease consequences and thus 
miss important sequelae when only focusing on the acute disease state, or use attributable 
(etiological) fractions of subsequent health states, making regular assessments time and 
resource consuming [111, 112]. Furthermore, as in the current GBD study, future sequelae, 
e.g. liver cancer due to hepatitis B, are included in the estimates but at the end are counted as 
part of the non-communicable disease burden. This is surely a matter of perspective, because 
from the perspective of current health-care needs it is important to know how many liver 
cirrhosis cases are currently prevalent, without paying particular attention to the initial cause 
of the disease. Taking the intervention perspective, and estimating the pay-offs of 
interventions such as vaccination against hepatitis B, it is important to consider all the 
consequences and fully acknowledge them as being part of the infectious disease burden, 
because successful prevention of an infection or preventing the further spread of a pathogen 
reduces the disease burden not only from the acute infection but also from the ultimate 
consequences related to it. 
The second point is related to the fact that most estimates of disease burden are based on 
country-level epidemiological data and provide an average value for the whole country. This 
is important when comparing different countries from a broad perspective but, due to 
considerable health inequalities within countries, it is also necessary to provide estimates of 
disease burden at a sub-national level. These estimates can contribute to debates about local 
resource allocation and strengthen priority-setting processes by tailoring them to specific local 
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needs. Here it is of major importance to test the feasibility of the BoD approach, and 
especially SMPH and their components, for sub-national analyses with special focus on data 
availability and quality, and also to identify the strengths and weaknesses, as well as data 
demands, in order to investigate how well these measures of population health perform for 
sub-national purposes [2]. 
The third point elaborates on how public health can benefit from the two aspects described 
above. Taking the public health perspective and generating understanding of the value of 
population-based health indicators and how these can be used for the subsequent 
improvement of population health are the important aspects considered. Here especially the 
analytical application of the BoD approach will provide an additional benefit to the generally 
descriptive and cross-sectional analyses of the current burden. For public health projecting 
trends of population health development and the impacts of interventions is a helpful exercise 
to improve the preparedness of health systems for future threats, because at the moment 
updated projections are generally lacking or outdated [113, 114]. Population health 
measurements can provide sound additional information about the current and future impact 
of diseases on population health and can serve as the basis for further assessments such as 
economic analyses [109]. 
4. Research program and objectives 
The research program for the dissertation is guided by two major streams, as indicated by the 
desiderata identified from the current state of research and the need to provide supplementary 
estimates of disease burden a) for infectious diseases and b) at a sub-national level. The 
research presented here covers both the aspects of methodological adaptation and application 
with the aim of providing sound supplementary aspects broadening the scope of current 
research in the field of BoD. The overarching aim is to shed light on how population health 
and measures of disease burden can stimulate debate about priority setting in public health to 
provide a sound evidence base to inform health policy decision-making processes. 
The three major fields of research elucidated in Chapter Three will be covered by six articles 
published in peer-reviewed journals. Two of them will focus on the application of the burden 
of disease technique in sub-national BoD analyses, with major emphasis on using SEYLL. 
Four articles will focus primarily on the adjustment of the BoD methodology, and especially 
the DALY framework, towards infectious diseases and the application of the developed 
methodology from the perspective of descriptive epidemiology, as well as from the 
perspective of analytical epidemiology focusing on projections of the disease burden, 
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including the effects of demographic change and assumptions about the potential effects of 
intervention measures. 
The goals of this thesis were to apply the concepts of the BoD framework and provide 
specific and necessary estimates of disease burden by addressing important questions dealing 
with the two settings described. It was intended to add BoD estimates to areas where 
information is currently lacking, even though the necessary data to calculate the disease 
burden is available. It was also of importance to shed light on how the assumptions used to 
calculate the disease burden can influence the resulting priorities. 
 
The objectives of the thesis can be operationalized in the following guiding research 
questions:  
[1] How can the burden of disease approach be tailored to better meet the needs of infectious 
diseases? 
[2] Is the standardized framework applicable to a heterogeneous set of infectious pathogens? 
[3] How can burden of disease estimates be used to predict the future disease burden 
considering dynamic changes of the population and impact of intervention measures? 
[4] Is it feasible to use the burden of disease approach on sub-national levels and what are the 
major limiting factors? 
[6] What are the benefits of sub-national burden of disease assessments? 
[5] How do social value choices impact on estimates of disease burden? 
 
These objectives and the related research questions indicate that the research conducted and 
the articles published cover both the application of the burden of disease methodology and its 
further development. Thus, the presentation of the papers will highlight these two main aims. 
All the articles are also guided by the overarching aims of highlighting the importance of 
burden of disease assessments for public health and of providing further insights into data 
availability and quality, because burden of disease analyses are strongly dependent on data 
availability, quality and the reliability of the data sources used. Thus, methods for correcting 
and adjusting epidemiological input data will also be considered. 
5. Methodological concepts 
As the objectives of this dissertation encompass both methodological refinement and the 
application of the burden of disease approach this chapter will lay out the constructs of the 
BCoDE methodology to quantify the disease burden due to infectious diseases and it will also 
describe the SEYLL approach to measure the effects of premature mortality. 
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5.1. The BCoDE framework (Papers 1-2) 
This chapter describes the development of an appropriate methodology to estimate the disease 
burden of infectious conditions. It covers Paper one, describing the method developed and 
Paper two, presenting important implications for data adjustment when using the pathogen- 
and incidence-based DALY approach. The methodology presented here is closely tied to the 
European-based project “Burden of Communicable Diseases in Europe” (BCoDE) initiated by 
the European Center for Disease Prevention and Control (ECDC). Within the BCoDE project 
it was aimed to generate a methodology explicitly tailored for assessments of infectious 
disease burden and priority-setting purposes. With limited availability of comprehensive and 
comparable estimates of the disease burden in Europe, the focus of the project was to quantify 
the disease burden for 32 selected pathogens in all EU, EFTA and EEA member states by 
using a standardized framework [115]. 
 
The pathogen- and incidence-based DALY approach (Paper 1) 
The DALY measure as introduced by Murray and Lopez in the first GBD study, follows the 
disease-specific approach and thus estimates the burden for disease endpoints, giving lower 
priority to the actual etiology of a disease [22]. Many disease endpoints, however, might have 
distinctly different causes, which need to be tackled by diverse prevention and intervention 
strategies in the field of public health. Especially for infectious conditions, which depending 
on the causative agent/pathogen have highly heterogeneous characteristics, natural disease 
histories, and prevention and treatment options, it is important not only to consider the acute 
infection with a pathogen as one disease endpoint but also to include all the multiple 
endpoints that are associated with the initial infection but occur either as short-term or, in the 
case of long chronic or latent conditions, as long-term consequences several years after the 
infection. In order to capture the comprehensive disease burden of infectious conditions the 
methodology used has to accommodate both aspects and should be able to summarize both 
effects. Therefore, the pathogen-based DALY approach is an appropriate measure because it 
estimates the years of healthy life lost according to the natural history of a disease [28, 115-
117]. The prerequisite for calculating the DALYs in the pathogen-based approach is a set of 
natural history models that from now on will be referred to as outcome trees. These outcome 
trees form the backbone of the methodology and are a qualitative representation of the natural 
history of a disease. Outcome trees include the outcomes of acute illness and all relevant 
short- and long-term consequences, referred to from now on as sequelae. In an outcome tree, 
which starts with exposure to a pathogen, all health outcomes are ordered by time and linked 
by conditional probabilities describing the consecutive flow from one health outcome to the 
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next (see Figure 3). In addition, where necessary a health outcome can be further 
differentiated into several health states describing different severity levels (e.g. mild, 
moderate, or severe) or health states that present a complicated case. For the outcome trees 
only sequelae with sufficient evidence to be caused by the initial infection were considered 
[118]. To propagate the identified uncertainty around the conditional probabilities the 
parameters were assumed as a distribution of values. Depending on the available data, 
distributions (e.g. uniform, PERT, beta) were selected for the parameters and the Monte Carlo 
technique was used to model uncertainty and estimate the 95% uncertainty intervals (UI). 
The natural start of an infection is the exposure to a pathogen. However, this event is not 
easily measurable and thus not covered by available health statistics from surveillance 
systems. The point at which health statistics become available is when an infected person 
develops symptoms and seeks health-care services. Surveillance systems for many pathogens 
with mandatory reporting mechanisms capture those cases, which in most of the infectious 
conditions can be considered as acute incident cases. This might not hold for pathogens with 
chronic disease courses where differentiation between acute and chronic infections is difficult. 
Having the surveillance data for many infectious diseases at hand, and using the pathogen-
based DALY approach, it was decided to use the incidence-based DALYs. The entry point for 
incidence data in the natural history models is the orange box in the outcome tree labeled 
“acute infections” (see Figure 3). Technically the DALYs are then calculated for all health 
outcomes included in the outcome tree. To estimate the DALYs the YLDs for non-fatal health 
outcomes and YLLs for the health outcomes leading to death were calculated separately. 
The original formula for YLDs was adjusted, resulting in the following representation: 
[5] sãl
sã
l
l
sa
l wtnYLD
,,, *    2 
The adjusted formula for YLLs reads as follows: 
[6] sãl
l
sa
l edYLL
,,    3 
All input parameters in both YLD and YLL formulae were chosen to be age (a) and sex (s) 
dependent when such information was available, where a stands for age at infection and ã for 
age at onset of a condition or death. The outcome tree models and necessary DALY formulae 
                                                 
2 YLDs are estimated for each health outcome (l) by multiplying the number of incident cases (n) by the 
disability weight (w) for a specific health outcome (l) and the duration of the disabling condition (t) (formula 5). 
3 YLLs for those health outcomes (l) that can lead to death, are estimated by multiplying the number of fatal 
cases (d) for a specific health outcome (l) for an infection acquired at age (a) by the remaining life expectancy 
(e) at age ã (formula 6). 
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were implemented in Microsoft Excel and the add-on software @Risk was used for 
probability modeling. 
 
Measuring the underreporting and under-ascertainment for infectious disease data (Paper2) 
As incidence data were the central but also very sensitive input to the models a careful 
examination of data availability and quality was necessary to ensure rigorous estimates of the 
number of incident cases. Even though data availability and quality in many European 
countries and for the diseases with mandatory reporting is extremely high and national health 
institutes provide detailed data sets stratified by age and sex, it is also known that surveillance 
systems, as they are currently in place, are selectively affected by different degrees of 
underestimation and the data reported might only represent the tip of the iceberg as many 
infections might go undetected. There are several reasons for underestimation, which can be 
broadly differentiated into underreporting and under-ascertainment. Under-ascertainment 
(community level) refers to cases that do not seek health-care services because of mild 
symptoms and knowledge about the self-limiting characteristic of a disease or asymptomatic 
disease course. The latter is especially important for diseases with sequelae from 
asymptomatic infections. Furthermore, asymptomatic infections might also serve as a 
reservoir for further infections and thus cause substantial disease burden. Underreporting 
(health-care level) refers to cases that do seek health care, but due to a) failure in diagnosis 
(no diagnosis at all or misdiagnosis) or b) failure in notification (no reporting at all or 
misreporting) are not fully, or correctly, reported to the national health surveillance systems. 
Underestimation can thus selectively impact on the number of incident cases reported by 
national and international bodies. Estimating the “true” incidence is essential, especially when 
it forms the backbone of disease burden. Thus, it becomes necessary to correct the reported 
data. As a part of the BCoDE study it was decided to use country, sex and age-specific 
“multiplication factors” (MF) to correct the raw incidence data. These MFs are based upon 
information from different kinds of studies that allow the derivation of a correction factor. 
One example is community-based studies which aim to capture pathogen carriage or infection 
in a, preferably representative, sample of the population. Comparing the estimates from these 
studies with cases notified, an MF can be derived, correcting these numbers. Another type of 
study is serological surveys that test biological samples and detect the sero-incidence and 
sero-prevalence of an infection. The advantage of serological testing is that, depending on the 
pathogen, detailed information on e.g. symptomatic, asymptomatic, past, acute or chronic 
infections can be gathered. These kinds of studies, when combined with a questionnaire 
instrument, are especially important for pathogens with asymptomatic and chronic infections 
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that can lead to sequelae (e.g. hepatitis B, Chlamydia) to estimate the 
symptomatic/asymptomatic fraction. A third type of study is the returning traveler study. 
Here, the risk of infection for travelers from one country (A) visiting another country (B) is 
estimated by taking the number of infected travelers returning to their home from country B 
from surveillance records as a numerator, and the total number of travelers from country A 
visiting country B from travel pattern databases as the denominator. This measure of risk can 
then be used to generate an adjusted estimate of incidence in country B. Comparing this 
estimate with the number reported in the national surveillance records of country B, an MF 
can be obtained to correct the reported data. A final type of study mainly covering the effects 
of underreporting, is the capture-recapture study. These studies combine different data sources 
that capture incidence, such as hospitals, general practitioners, or laboratory data and use 
unique personal identifiers to crosslink the cases, identify any overlap between data sets and 
quantify the number of cases not captured by each data collection system. Based on these 
estimates, a “true” incidence can be estimated. To obtain MFs from published studies, 
disease-specific search strings were developed and literature databases were systematically 
screened for appropriate studies. Data on the different types of studies as identified from 
pathogen-specific literature reviews, served as the initial input to derive, in the best case, 
country-, age- and sex-specific multipliers to correct for underestimation in the national 
surveillance systems. Having an MF at hand, the raw incidence data were corrected and used 
as the initial model input to calculate the pathogen- and incidence-based DALYs. 
5.2. Standard expected years of life lost as a measure of premature mortality 
As described in the previous chapters, most disease-burden estimates are restricted to the 
national level and sub-national assessments are rarely available; however, they are necessary 
because understanding regional differentiation of the disease burden is an important step 
towards gaining detailed information about health patterns. There are several epidemiological 
indicators that, at least in high-income countries, are available at a sub-national level and 
mortality statistics from vital registration systems allow for small-scale analyses. However, 
the simple death counts or death rates that are mostly used to present the patterns of mortality 
associated with disease burden are insufficient measures as they do not account for age at 
death and do not consider the actual loss of healthy years. 
The SEYLL metric which reflects the mortality component of the DALY, quantifies the years 
of life lost due to premature death in a population. Using a normative health goal, the SEYLL 
measures the gap between the ideal health goal and observed mortality patterns. In the case of 
the SEYLL, the difference (in years) between the remaining life expectancy at age of death, 
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and the age of death itself is the outcome of interest. Technically, the normative health goal 
for the SEYLL is set to life expectancy values derived from a standard life table (West Level 
26). The formula fo undiscounted and not age-weighted SEYLL is the following: 
 
ሾ6ሿ	ܵܧܻܮܮ ൌ ܰ ൈ ܴܮܧ௫		4 
Introducing age-weighting and discounting, the resulting formula is: 
 
ሾ7ሿ	ܵܧܻܮܮ ൌ ܰ	ܥ݁ሺ௥௔ሻ/ሺߚ ൅ ݎሻ² ቂ݁ିሺఉା௥ሻሺோ௅ாା௔ሻሾെሺߚ ൅ ݎሻሺܴܮܧ ൅ ܽሻ െ 1ሿ െ ݁ିሺఉା௥ሻ௔ሾെሺߚ ൅ ݎሻܽ െ 1ሿቃ	  5 
Cause of death data serve as the initial input. The raw data are redistributed from the original 
classification (e.g. ICD 10) to the GBD classification systems and are corrected for miscoding 
of death causes. 
6. Empirical findings 
The empirical findings of the thesis identify the potentials and challenges of both approaches 
for increasing the availability of population health estimates. The results presented fill 
existing gaps because assessments of burden of disease using composite health measures are 
not available either for infectious diseases in Germany, or at the sub-national level for NRW 
or Hong Kong. 
6.1. Applying the BCoDE methodology (Papers 3-4) 
To test the feasibility of applying the pathogen- and incidence-based approach, two strategies 
were chosen following two objectives. The first objective was to use the framework to 
produce a set of descriptive estimates for Germany and four selected pathogens (Paper 3). The 
second objective was to use the approach in an analytical framework to predict the future 
disease burden of two selected pathogens in the Netherlands with an additional focus on the 
potential impact of intervention strategies (Paper 4). 
To test the applicability of the pathogen- and incidence-based DALY approach in Germany, 
hepatitis B virus, influenza virus, measles virus and salmonella spp. were chosen for the 
experiments (details on the model specifications can be obtained from the supplementary 
material in the articles). These pathogens were selected as they differ not only in their 
characteristics (e.g. natural history, transmission) but also in terms of the availability of 
vaccines and their different occurrence (e.g. epidemic, endemic, or outbreak related). Raw 
                                                 
4 SEYLL are calculated by multiplying the number of deaths (N) at a certain age of death with the remaining life 
expectancy (RLE) at age of death (x) [58]. 
5 N is the number of deaths, r is the discount rate (0.03), C is the age-weighting correction constant (0.1658), e is 
a constant (≈ 2.718), β is the parameter from the age-weighting function (0.04), a is the age at death and RLE the 
remaining life expectancy at age of death [39]. 
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notification data (average) for the years 2005 to 2007 were corrected for underestimation and 
served as the initial input to the models. The average reported number of acute incident cases 
per year was 1,137 for hepatitis B virus, 11,772 for influenza virus, 1,217 for measles virus, 
and 52,322 for salmonella spp.. After correction for underestimation 16,170 (95% UI: 
14,438–17,909) cases of acute hepatitis B, 1,236,269 (95% UI: 1,120,752–1,354,268) cases of 
acute influenza, 2,840 (95% UI: 2,738–2,925) cases of acute measles, and 565,981 (95% UI: 
477,435–657,638) cases of acute salmonella infections were modeled. The highest burden 
was estimated for influenza virus, with 33,116 (95% UI: 29,504–36,849) DALYs/year. 51.6% 
of the burden was due to the effects of premature mortality. DALY-rates were higher for 
males. with 41.3 (95% UI: 34.7–47.6) DALYs/100,000 as compared to 39.3 (95% UI: 33.5–
45.1) DALYs/100,000 for females (for more details see Figure 4). The highest DALYs were 
estimated for the acute infection with 29,439 (95% UI: 26,283–32,708) DALYs/year 
accounting for 88.9% of the overall disease burden. 11.1% was due to long-term 
consequences caused by acute respiratory distress syndrome (1,878 (95% UI: 1,647–2,117 
DALYs/year)) and sepsis (1,794 (95% UI: 1,573–2,021) DALYs/year). The second highest 
disease burden was estimated for salmonella spp., with 19,115 (95% UI: 14,803–24,328) 
DALYs/year. In contrast to influenza, the major part of the disease burden was due to the 
effects of morbidity, with 61.2% of the overall DALYs related to the YLDs. Higher DALY-
rates were estimated for the female population, with 24.1 (95% UI: 16.9–34.0) 
DALYs/100,000 in contrast to 22.2 (95% UI: 15.5–31.1) DALYs/100,000 for males. Acute 
illness (gastroenteritis) had a 44.4% share of total DALYs indicating the considerable impact 
of the sequelae, mostly due to irritable bowel syndrome (IBS) 10,459 (95% UI: 8,593–
12,528). Reactive arthritis (ReA) also contributed to the sequelae burden, with 173 (95% UI: 
102–257) DALYs/year. The third largest burden was estimated for hepatitis B virus. 
According to our model for hepatitis B virus we estimated 8,780 (95% UI: 7,335–10,163) 
DALYs/year related to infections with hepatitis B, with 55.1% (4,798 DALYs) due to YLL. 
Hepatitis B showed a higher burden for males, with 12.4 (95% UI: 9.9–15.2) DALYs/100,000 
as compared to females with 8.8 (95% UI: 6.7–11.1) DALYs/100,000. The sequelae that were 
the largest contributors to disease burden were hepatocellular carcinoma (2,795 (95% UI: 
1,833–3,810), chronic hepatitis (2,763 (95% UI: 2,248–3,097) DALYs/year), and 
decompensated cirrhosis (2,182 (95% UI: 1,791–2,594). Overall, only 2% of the overall 
burden was related to the acute illness, indicating the importance of the sequelae in causing 
high DALYs for hepatitis B. Within the four selected pathogens, the lowest disease burden 
was estimated for measles virus, with 740 (95% UI: 413–1,066) DALYs/year, with most of 
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the DALY due to YLL (90.8%) and the acute illness (93.0%). The disease burden of the long-
term consequences due to encephalitis and post-infectious encephalomyelitis were estimated 
at 16 (95% UI: 16–17) and 33 (95% UI: 20–45) DALYs/year, respectively. 
The results showed that it was feasible to apply the pathogen- and incidence-based DALY 
approach to the four selected pathogens (see Table 1 for an overview). Furthermore, these are 
the first estimates of the infectious disease burden for Germany measured by DALYs. Due to 
a lack of overall estimates for the disease burden in Germany, comparison of the results is 
limited to these four pathogens. However, the estimates clearly highlight the importance of 
including the effects of morbidity and especially emphasize the contribution of short- and 
long-term sequelae. Here, when looking at the upper extreme case of hepatitis, not 
considering long-term sequelae would result in an underestimation of the disease burden by 
98%. 
The estimates presented in Paper three have already nicely shown the value of burden of 
disease estimates for infectious disease as modeled with the pathogen- and incidence-based 
DALY approach. The estimates provided include the acute stage, as well as short- and long-
term sequelae and are thus able to present the total impact of infectious diseases on population 
health. From a preventive point of view, where the aim could be to introduce effective 
prevention measures such as vaccination to avoid new infections, the introduced approach can 
also be used in an analytical exercise to predict future burden and can include the expected 
impact of intervention and prevention measures. Estimating these kinds of impact in the 
pathogen- and incidence- based DALY approach would not only consider the cases of acute 
illness that have been prevented but would also include the potential benefits of intervention 
strategies in avoiding the heavy burden of sequelae and thus might result in more appropriate 
estimates of the effect of prevention measures. 
Therefore, Paper four aimed to predict the disease burden of two pathogens, hepatitis B and 
influenza virus in the Netherlands from 2000 to 2030. To increase the value of these 
predictions two major aspects of demographic development were taken into account when 
estimating the future burden. Population growth and aging were considered, whereas a steady 
state for disease incidence was assumed based on the average of reported incidence rates in 
the Netherlands between 2000 and 2010. The disease burden was modeled using the 
pathogen- and incidence-based DALY approach. To address the effect of intervention 
measures for hepatitis B, one scenario introduced a 2% per year decrease in incidence for all 
age groups (simulating the effects of an increase in vaccination coverage for all age groups) 
and in contrast a second scenario assumed a decrease of 5% per year only in the population 
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younger than 15 years (simulating the effects of age-targeted vaccination). To estimate the 
effect of age-targeted vaccination for influenza virus in the age group 60+, three scenarios 
were calculated with decreases in incidence in this age group of 5% and 2% per year 
(simulating uptake of vaccination coverage) and increases in incidence by 2% per year 
(simulating declines in vaccination coverage). In our baseline scenario for hepatitis B virus, a 
slight increase in disease burden from 1,196 (95% UI: 1,003–1,328) DALYs/year in 2000 to 
1,343 (95% UI: 1,194–1,493) DALYs/year in 2030 was estimated. Compared to a static 
approach, where population size, age distribution and life expectancy were kept constant, an 
overall higher burden in the dynamic approach was estimated, with DALYs being from 1.34-
fold higher in the year 2000 up to 1.50-fold higher in 2030. The scenario simulating a 2% 
decrease of incidence in all age groups resulted in the strongest decline of disease burden, by 
32%. In contrast, the 5% decrease of incidence in the population aged less than 15 years only 
resulted in a marginal decrease of 3%. The baseline scenario for influenza yielded a 
remarkable increase from 22,712 (95% UI: 21,132–24,290) DALYs/year in 2000 to 51,609 
(95% UI: 48,212–55,198) DALYs/year in 2030. Compared with the static approach, an 
identical disease burden was estimated for the dynamic model for the year 2000 but a 2.27-
fold higher disease burden for 2030. In the scenario analyses a decrease of 23% and 45% in 
the disease burden was estimated when assuming a 2% and 5% decreasing trend in incidence 
rates per year (for the age group 60+), respectively. In contrast, an increase of 2% per year in 
incidence rates would result in the disease burden being 34% higher than estimated in the 
baseline scenario. 
The results presented clearly show that a) dynamic demographic processes and b) intervention 
measures such as vaccination can have a huge impact on infectious diseases. The results 
especially highlight the impact of universal vaccination for hepatitis B and age-targeted 
vaccination for influenza. The results indicated that, for predicting the future disease burden 
from a population-health perspective, SMPH are a very useful alternative to classical 
epidemiological indicators because they include the full impact of diseases on health. 
6.2. Sub-national burden of disease assessments in high-income areas (Papers 5-6) 
Papers five and six are related to the aim of testing the feasibility of applying the burden of 
disease approach, and especially a standard measure of premature mortality, at a sub-national 
level. Both articles focus on the assessment of disease burden and present patterns of causes 
of premature death for high-income areas located in different regions of the world. The 
articles highlight the advantages and challenges of the approach and compare the estimates to 
standard measures of mortality. Both studies close existing data gaps by providing sound 
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additional information on population health. Paper five presents results generated for NRW, a 
federal state of Germany, and paper six lays out estimates for the special administrative region 
of Hong Kong in China. Paper six in particular extends the value of the SEYLL estimates by 
including scenario analyses highlighting the choice of assumptions in the estimation process. 
Paper five focuses on the implementation of the SEYLL concept at a sub-national level and 
highlights the importance of taking into account the age of death and thus the years lost due to 
premature death [32]. Estimates of the burden due to premature death in Germany are 
generally incomplete at both national and sub-national levels. In addition, indicators such as 
the Potential Years of Life Lost (PYLL) are used, which are not adequate to capture the full 
impact of premature mortality, because they use a potential limit to live (e.g. 75 years) and 
thus are not able to capture the benefits of interventions aiming at preventing deaths above 
this age limit. [119]. Therefore, the research objective of this study was to estimate the burden 
of disease due to premature mortality by applying the methodology at a sub-national level and 
calculating the SEYLLs for NRW. The study used mortality and cause of death data from 
regional and national statistical health authorities. Despite full coverage of cause of death 
data, a considerable number of cases was attributed to ICD codes that were either generally 
unspecific (e.g. ill-defined categories coded R00–R99 in the ICD 10) or could not be 
considered the primary cause of death (e.g. cardiac arrest). Therefore, these data were 
reallocated to specific codes according to an algorithm provided by the methodological 
constructs of the GBD study [83, 120]. Furthermore, the data was also redistributed to meet 
the GBD classification system, as presented in Chapter Three. The SEYLL for 2005 were 
calculated using a three percent time discount and uniform age weights to achieve comparable 
estimates to other existing BoD studies. In total, a loss of 1.75 million SEYLLs was estimated 
for NRW, with higher shares observed for females (52.6%). The overall burden was mainly 
due to the effects of group two conditions, which accounted for 89.1%. Group one and three 
conditions had a share of 5.6% and 5.3%, respectively. These results highlight “ischemic heart 
disease” as the leading cause of premature death, with 321,617 SEYLLs, followed by 
“trachea, bronchus and lung cancers” (131,529 SEYLLs) and “cerebrovascular disease” 
(105,639 SEYLLs). Major differences were identified compared to standard death counts in 
the higher priority attached to “trachea, bronchus and lung cancers”, which represented the 
second leading cause of SEYLLs (ranked 3rd in death counts) and “liver cirrhosis” ranked 7th 
(ranked 11th in death counts) in NRW. In particular, the SEYLL estimates identified “self-
inflicted injuries” as important drivers of premature death for the male population ranking 
them 8th, whereas if using classical death counts this cause will not be one of the top ten 
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leading causes (ranked 13th) [32]. The results for NRW indicated typical patterns of premature 
mortality, comparable to other assessments in high-income areas. The results particularly 
highlighted diseases occurring at earlier stages of life and this indicates great potentials to 
intervene and reduce the years of healthy life lost due to premature death. 
The analyses for NRW were guided by the standard assumptions used in the GBD study. 
However, changing these assumptions can have considerable impact on the resulting priorities 
and thus, it is important to show the impact of the different value choices on the estimates of 
SEYLL. While its primary focus is on estimating the sub-national disease burden due to 
premature death in Hong Kong Paper six also presents the quantification of effects introduced 
by age-weighting, time-discounting and by using an alternative standard life expectancy [32]. 
After consulting misclassifications of reported death cases and redistributions of deaths to the 
GBD classification system, SEYLLs were calculated with no time-discounting and uniform 
age weights in the baseline scenario. The assumptions about value choices were considered in 
various scenario analyses. Overall, the baseline scenario yielded 524,707 SEYLLs for Hong 
Kong, SAR in the year 2010, with a greater share observed for males, at 55.6%. 78.8% of the 
SEYLLs were estimated to be caused by group two conditions and represent the majority of 
years of healthy life lost due to premature death. Group one and three conditions contributed 
8.5% and 12.7% to the SEYLLs, respectively. At the second level of disaggregation, 
malignant neoplasms (39.1%), cardiovascular diseases (21.7%) and respiratory infections 
(8.9%) were the leading cause groups, accounting for about 70% of all SEYLLs. At the third 
level of disaggregation “trachea, bronchus and lung cancers” (52,242.1 SEYLLs; 10.0%), 
“ischemic heart disease” (51,542.2 SEYLLs; 9.8%) and “lower respiratory infections” 
(46,503.2; 8.0%) were the three major leading causes of SEYLLs. Despite the fact that Hong 
Kong is a high-income country, the epidemiological transition seems to be not fully advanced 
when compared to the results of other studies in high-income areas. “Lower respiratory 
infections” still cause major decrements in population health. Overall, the share of SEYLLs 
due to group one conditions is still considerably higher than in other high-income areas such 
as Spain (6.4%) and Germany (5.6%) [32, 91]. Contrasting further, “trachea, bronchus and 
lungs cancers” were identified as the leading cause of SEYLLs in Hong Kong, which again is 
different from other studies which identified “ischemic heart disease” as the leading cause 
[32, 93]. This might be explained by the effects of past and current smoking habits in Hong 
Kong with high overall smoking rates in the past and currently high rates still observed in 
men aged 30+. If death counts were consulted “trachea, bronchus and lung cancers” would 
only rank 3rd and would be surpassed by “lower respiratory infection” (1st) and “ischemic 
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heart disease” (2nd). Furthermore, “self-inflicted injuries” (suicides) were identified as an 
important driver of SEYLLs in Hong Kong, being ranked 6th and 7th for males and females, 
respectively. Using death counts, “self-inflicted” injuries would only rank 9th for men and 17th 
for women and thus would grossly underestimate the priority of this condition. For women, 
SEYLLs drew greater attention to two important cancers sites, with rank changes for breast 
cancer from 8th to 6th and liver cancer from 7th to 4th position. 
In order to consider the effect of age-weighting and discounting three scenarios were 
calculated. In addition to the baseline estimates (0,0) scenarios with (I) a three percent time-
discount and non-uniform age weights (3,1), (II) a three percent time-discount and uniform 
age weights (3,0), and (III) no time-discount and non-uniform age weights (0,1) were 
calculated. Scenario I resulted in the greatest reductions in SEYLLs of 51.6% indicating a 
large impact on the overall burden (see Figure 5). The analysis also highlights that time-
discounting and age-weighting had a selective impact on the different disease groups. Group 
one conditions, which mostly affect the very young and very old segments of the population, 
received greater decrements, with reductions in SEYLLs of 55.1% as compared to 51.7% and 
45.9% for group two and three conditions, respectively. The lowest reductions in the overall 
burden were estimated for scenario II, with an overall decrease of 25.5% compared to the 
baseline SEYLL. Even though the overall decrease is the lowest compared to the other 
scenarios, there was an obviously imbalanced selective impact on the three main cause 
groups. Group one and two conditions showed comparable reductions of 22.8% and 24.4%, 
respectively. Group three conditions, however, were reduced by 39.8%, because most of the 
injuries considered in this group occur in younger age groups. In contrast, the scenario only 
using non-uniform age weights (III) that give higher weights to people in the most 
economically productive ages, gave an increase in priority to “self-inflicted injuries” from 5th 
to 3rd rank, even surpassing “lower respiratory infections”. Changing the global standard for 
life expectancies resulted in a considerable increase of disease burden, of 10.8% which was 
mostly related to higher values for life expectancy, especially for the female population. Here 
the life expectancy was between 1.5 and 3.5 years (depending on age group) higher than in 
the global standard. Thus, the increases in the SEYLLs were also higher in the female 
population with a rise of 15.1% as compared to 7.4% for males. 
Both studies have shown that applying the SEYLL measure at a sub-national level is 
generally feasible. The results are of particular interest for local planning of interventions, and 
including the information about age at death offers new perspectives, presenting the SEYLLs 
as a sound alternative for going beyond standard measures of mortality. 
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7. Discussion 
This discussion is guided by the general question of why population health measures such as 
the DALY and its components are important for research and prioritization processes in 
public health. It also considers how setting specific adjustments increase the value of these 
estimates and can help to identify the important drivers of ill health. This section will also 
highlight how SMPH can give added value to overall health statistics and how important 
availability and quality of data is to generate reliable and evidence-based estimates. The 
discussion will also accentuate the significance of going beyond national estimates and argues 
that, even though the one-size-fits-all methodology in general might be desirable at a global 
scale, to accommodate heterogeneous sets of conditions, there is a growing interest in more 
specific and thus more adequate measures, when target-specific interventions at the 
population level are intended. 
Indisputably, the health of each individual is a key value and maintaining a good health status 
of each individual is the main goal of health services. Nevertheless, the individual health 
perspective only provides a fragmented view and does not allow the creation of a 
comprehensive and comparable overview of the health situation of a population. These 
estimates are needed in order to generate a general understanding of health trends, the 
distribution of ill health in a population and the effects of health determinants at a broader 
level. Furthermore, many public-health intervention measures operate at the population level 
and not only result in health benefits for a single individual but can also help to improve the 
health of an entire population. It becomes evident that population health measures, such as the 
DALY and its components, that allow to capture the comprehensive health status of a 
population can serve as markers for the overall health status. They can also, in the long run, 
be very sensitive indicators of the health trends introduced by demographic, epidemiologic 
and risk factor changes, as well as provide valuable information about the success or failure of 
public-health measures or the overall performance of health systems. 
In the past, a large number of donor agencies have spent huge amounts of resources to 
improve the health status across the world, but since the financial downturns in almost all 
areas of global society, especially since the recent financial crisis in 2008, all sectors face 
budget cuts and so the health-care sector in no exception [121, 122]. Especially in the health 
sector, demands and costs have increased substantially, whereas spending on health has 
remained quite stable, indicating that mechanisms of priority setting are in place and decisions 
are made based on more or less solid grounds [123]. There are several approaches to 
allocating scarce resources, ranging from data-driven approaches, where indicators allow 
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setting up priority listings, to decisions based on the consensus of experts, which might lead 
to choices guided by specific personal interests (e.g. for a certain disease or treatment) [124-
126]. To reduce the number of biased decisions, standardized health indicators of disease 
burden, such as the DALY and its components, that make use of a wide array of available data 
on diseases and injuries, are an increasingly favored source of information for health policy 
decision making, and also for setting priorities in the field of health research. Despite, the 
overarching objectives of the GBD study to capture the global health status, the methods used 
in the study also have great potential to expand their initial scope. Going beyond the one-size-
fits-all solution and national boundaries provides sound and valuable additional information 
that will help the public health community not only to identify the major drivers of disease 
burden but also to highlight areas where investment in prevention and intervention measures 
has great potential to improve health status. 
This thesis has shown that adjustments in the methodology for measuring the disease burden 
of infectious conditions and expansion its scope to sub-national level provide valuable 
insights into population health patterns for public health. The burden of disease framework, 
and especially the DALY measure, are very flexible and can be adjusted to meet specific 
needs. This is of major importance, especially for infectious diseases because they present 
with very specific and, depending on the pathogen, distinctly different characteristics. The 
currently available assessments of disease burden, use the disease-specific DALY approach to 
a great extent, capturing the disease burden related to disease endpoints (e.g. liver cirrhosis, 
hearing or vision loss) rather than to the etiological cause (e.g. a pathogen) [20, 70]. For 
infectious conditions this means that the burden of acute infections are mostly covered, but 
other disease endpoints that might have an infectious etiology are either not considered as part 
of the infection [20], or even if related to a certain etiology, simply not counted as being part 
of the infectious disease burden [70]. The idea behind is, that in general, to capture the current 
state of disease burden, which is relevant to allocate current spending on health care, for many 
disease endpoints the initial cause is probably not of an issue because the conditions may 
require similar treatment. This perspective loses strength, however, when the view is changed 
from the curative to the preventive perspective. Here it becomes evident that the etiology of a 
disease outcome is crucial, especially when estimating the full impact of intervention 
measures. It is therefore necessary that the approach taken to measure infectious disease 
burden accommodates the acute infection as well as the health outcomes considered as part of 
the natural history. The pathogen- and incidence-based DALY approach used for the analyses 
in this thesis has the benefit that, on the one hand, it covers the acute illness and, on the other 
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hand, it estimates the potential future burden arising after the initial infection [28]. By 
including this information, measurements of the impact of interventions aiming at avoiding 
the initial infection would consider the entire disease burden of that infection. When this 
methodology is applied at a national level for Germany, the results clearly show that sequelae 
contribute significantly to the disease burden, especially for diseases with long chronic phases 
such as hepatitis B, where potential sequelae occur after a long period of more than 40 years, 
but also for salmonellosis where sequelae develop shortly after the acute infection [30]. In 
both cases the disease burden caused by the sequelae is generally higher than the burden 
caused by the acute illness, accounting for 98% and 55.6% of the DALYs for infections with 
hepatitis B virus and salmonella spp., respectively [30]. This is not only important for 
measuring the disease burden of these pathogens but it is also a crucial issue when economic 
aspects are taken into account. Estimating the impact of prevention measures and only 
focusing on avoiding the acute illness will result in skewed cost-effectiveness and may result 
in the denial of any prevention measures. 
Using the pathogen-based approach and the related outcome trees can further increase the 
preparedness of health-care systems. Using information about duration for the health 
outcomes, this approach also allows to track the evolving potential future disease burden [31]. 
This is of major importance for diseases with long chronic or latent stages, such as infections 
with the hepatitis B virus or HIV. The pathogen-based approach allows modeling of the 
potential future burden along time and, in the case of a hepatitis B infection, indicates that 
after a long period of chronic infection with an intermediate disease burden, a peak of disease 
burden arises at about 40 years after infection, mainly induced by the long-term sequelae such 
as liver cirrhosis and hepatocellular carcinoma (see Figure 6). Health-care services can profit 
from these insights, gaining the opportunity to foster preparedness for the impact of a future 
burden due to sequelae arising in the future. 
Different epidemiological data can serve as the input to calculate the DALY, but when using 
the pathogen-based approach, a necessary prerequisite is to take the incidence perspective and 
use incidence and not prevalence data as the central input for the DALY calculation [28]. 
With data on the prevalence of an infection, the time point of initial infection with a pathogen, 
and thus the concrete entering point/time in the natural history model is generally not known 
and thus the starting point in the outcome tree cannot be determined, hampering consistent 
calculations of the disease burden. In contrast, using incident cases can limit the 
comprehensiveness of the chosen modeling strategy, especially for chronic infections where 
prevalent infections give rise to the current disease burden. With the incidence-based 
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approach, prevalent infections are not included. For hepatitis B, this is of major importance 
for low-endemic countries with considerable numbers of infected migrants entering the 
country from high-endemic areas. Again, the initial perspective and the modeling objectives 
play the most important role. When the aim is to capture the current disease burden and the 
resulting priorities of interest are to examine current health-care demands (and costs), the 
prevalence and disease endpoint approach is the adequate choice [70]. Whenever the 
perspective is shifted to deal with aspects of prevention and intervention strategies, especially 
in the case of infectious diseases, the incidence approach is the more appropriate choice. The 
incidence approach allows not only to capture the current disease burden but, combined with 
the pathogen perspective, it also enables us to include the potential future burden of sequelae. 
This potential burden is a major issue when avoiding the initial infection is a primary focus of 
decision-making processes. Another argument for using the incidence-based approach for 
infectious diseases is that incidence is a more sensitive indicator of the current epidemiology 
of a disease. In contrast to prevalence, which is generally defined as stock measures, 
incidence is a flow measure and can capture dynamic conditions such as infectious diseases 
more precisely [127]. For instance, infectious diseases, often presenting with short durations, 
are not easily captured by point or period prevalence, especially when the acute phase of an 
infection is of major interest. 
Testing the methodology for four pathogens in Germany indicated that the basic methodology 
developed is generally applicable to conditions with varying characteristics. With a 
comprehensive assessment of both acute illness and the sequelae following the infection, by 
means of outcome trees, the whole spectrum of infectious pathogens can be covered. The 
results for Germany already indicate that comparisons between the four pathogens are 
feasible, and reveal the urgent need for burden of disease estimates for all remaining 
pathogens in order to arrive at a comprehensive assessment of the infectious disease burden in 
Germany. Using the DALY as the outcome metric, the effects of mortality and morbidity can 
be measured in one single unit of measurement. Adjustments towards the pathogen-based 
perspective then allow us to identify differences in the disease burden due to the relevance of 
acute illness and sequelae (see Figure 7). Without information about non-fatal health 
outcomes (YLD), the disease burden would be underestimated for infections with hepatitis B 
virus by 44.9%, with influenza virus by 48.4%, with measles virus by 9.2% and by a huge 
61.2% for infections with salmonella spp., indicating an important added value compared 
with classical epidemiological indicators. Furthermore, using the adjusted approach enables to 
include asymptomatic infections, which in the case of hepatitis B give a large rise to disease 
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burden; and not considering these asymptomatic cases would result in an underestimation of 
disease burden by 80.1% [30]. The estimates provided for Germany and future estimates for 
the remaining 28 pathogens might offer new perspectives and can foster debate about current 
priorities and the methods used to determine these priorities. 
The purpose of the methodology developed in this research was to accommodate the 
characteristics of infectious diseases and to provide estimates of the burden of disease that 
better reflect the current situation of infectious conditions. The resulting estimates already 
provide additional insights for the descriptive epidemiology and fill existing data gaps. Taking 
the public health perspective, descriptive estimates are the first and necessary step towards 
unfolding the health status of a population. Information about the current state of health is 
important for planning current health services, but health systems also need to be prepared for 
future trends and upcoming needs and thus require information about the development of the 
future disease burden. This requires analytical steps to be taken and the pathogen- and 
incidence-based DALY approach allows going beyond descriptive analyses. It can be utilized 
to estimate the impact of different trends from a population perspective, which was also 
shown by this thesis. There are different trends impacting on the future development of a 
disease. Some trends are inherent in a population, such as those trends described as 
demographic, epidemiologic and risk transitions. Other trends are related to the dynamic 
nature of infectious diseases and make predictions of future burden a complex undertaking 
where several determinants and their uncertain developments need to be considered. Two very 
important aspects of infectious disease development are certainly demographic changes and 
the implementation of interventions strategies. Demographic changes in high-income 
countries have led to large shifts in the population structure towards older ages and the 
predictions presented for the Netherlands show that by 2030 the share of the age group older 
than 75 years will double from 6% (2000) to 12% [31]. With increasing age, the ability of the 
immune system to cope with infectious pathogens wanes, increasing the probability of elderly 
people attracting infections, which may also have more severe disease courses than infections 
attracted at younger ages, presenting with e.g. increased case-fatalities. Furthermore, the 
increased life expectancy of the population may also allow long-term chronic infections to 
reach their sequelae endpoints more often than in the past. Predictions of the future 
development of the infectious disease burden that take such effects into account are necessary 
and can help strategic health service planning to prepare for changing demands or to 
show/predict the impact of planned interventions. Combining the incidence- and pathogen-
based DALY approach with a demographic model indicated that this standardized approach 
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can be applied to diseases with different natural histories. The study compared infections with 
hepatitis B virus to infections with influenza virus and showed how demographic change 
impacts on the future disease burden. For hepatitis B, two major effects were identified. The 
first effect of the demographic change impacts on the most vulnerable groups for hepatitis B 
infections. Here we see a general decline in the vulnerable population size and thus a modeled 
decrease in the incidence. This would lead to a decrease in the disease burden over time, with 
respect to YLDs. However, increasing life-expectancy over time leads to a higher cumulative 
probability of the population to develop future sequelae. This in turn leads to an increase in 
the disease burden, mostly due to YLLs. Both effects level out and result in a moderate 
increase in the overall disease burden (DALYs) for hepatitis B virus [31]. For influenza, the 
effect of demographic change is mostly seen in YLLs, where the increase is closely related to 
the growth of the population aged 75+. Incorporating the effects of demographic changes has 
already provided important insights into the future development of the disease burden. 
However, from the public health perspective, the opportunity to avoid this future burden is 
crucial. Especially for diseases caused by hepatitis B and influenza virus, where effective 
vaccines are available, the impact of varying vaccination regimes on the future disease burden 
can stimulate debate by providing sound estimates of the potential changes in population 
health induced by these regimes. Though an exploration of the impact of vaccination regimes 
on population health, different scenarios can be investigated; for instance, contrasting the 
effects of age-targeted or universal vaccination. For infections with hepatitis B virus, it was 
estimated that reductions in the disease burden due to age-targeted vaccination regimes 
aiming at vaccination of the population under 15 years of age would be much lower than 
those achieved through the uptake of universal vaccination coverage [31]. For influenza, 
however, vaccination regimes aiming at the older segments of the population (60+) would 
result in remarkable reductions in the disease burden [31]. Using the pathogen- and incidence-
based DALY as an indicator for the impact of interventions extends the currently available 
estimates. The predictions presented here are, however, limited to the inclusion of a) 
demographic changes in the population and b) the impact of interventions. For pragmatic 
reasons (at least in the baseline scenario), we assumed a constant trend for the incidence and 
thus estimated the disease burden for an epidemiologic steady-state. With constant changes in 
the epidemiology of infectious pathogens, driven by genetic conversions of viruses or 
bacteria, changes in contact patterns within the society, changes in sexual behavior patterns 
and many other influences, describing future trends by retaining the steady-state assumption 
might result in under- or overestimation of the disease burden. All these factors are highly 
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uncertain and to a large certain extent not truly and precisely predictable. To predict the future 
disease burden of infectious diseases more accurately, infectious disease dynamics such as 
contact and mixing patterns in a population should be incorporated [128, 129]. Including such 
patterns would result in more rigorous estimates of future incidence and would in particular 
account for the potential spread of infections with asymptomatic disease courses. 
Another factor introducing considerable uncertainty is the quality of the data that is used for 
the calculations of disease burden. High-quality data is necessary to provide sound estimates 
of disease burden. This aspect is important for both mortality and morbidity data. Despite the 
full coverage of vital registration systems in high-income countries, the effects of 
misclassification/miscoding have a considerable impact on the mortality estimates for specific 
causes. Misclassification of causes of death is related to the fact that deaths are simply not 
coded correctly to the primary cause of death or are coded in residual categories resulting in 
many deaths not being correctly assigned to a cause or being assigned to a cause that per se 
cannot be a primary cause of death. In the GBD 2010 study, considerable numbers of death 
counts were considered to be in the so-called “garbage” coding groups, resulting in wrong 
coding of deaths ranging from 5.5% in Finland to 69.9% in Sri Lanka [130]. Within the GBD 
framework, concepts were developed that redistribute wrongly coded deaths to the 
appropriate locations [45, 120, 131]. This framework allows country-specific corrections of 
miscoding and thus is of importance in improving the data quality of mortality estimates. It 
can be assumed that the provided nationally specific correction algorithms might even be 
specific to sub-national coding practices. However, as correction algorithms are not available 
at this level, the corrections of the mortality data used for calculations of SEYLLs in NRW 
and Hong Kong were based on country-specific algorithms for Germany and China, 
respectively [32, 33]. Even though these redistributions are necessary to provide a correct 
overview of mortality patterns, Polinder et al. showed in their review of BoD studies that use 
DALYs as the main outcome measure, that several studies did not consider the re-allocation 
of ill-defined/garbage codes or simply did not report any redistribution [132]. 
Nevertheless, the quality of mortality data in countries with well-established vital registration 
systems is high. In contrast, the availability and quality of data with respect to morbidity is far 
from perfect and nationally representative estimates for many morbidity indicators are 
lacking. For instance, when considering infectious diseases, most high-income countries have 
installed sophisticated surveillance systems that capture trends for infectious diseases. The 
reporting protocols for capturing those diseases can be of a mandatory or voluntary nature. 
This already has a significant impact, as voluntary reporting is associated with a lower 
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likelihood of a case being ascertained and reported to the health authorities [29]. The findings 
of this thesis showed that, for infectious pathogens/diseases, underestimation is a crucial 
factor and the data provided by the surveillance systems only represent a small fraction of the 
“true” number of infections in a population [29]. When data from surveillance systems serve 
as the input for BoD models, it is therefore necessary to adjust for the underestimation 
prevalent in the surveillance data. Correcting for underestimation is strongly dependent on the 
pathogen studied, and the study performed in Germany showed that correction factors vary 
widely between 1.5 for acute measles infections and 26.8 for acute infections with non-
typhoidal salmonella spp. [30]. This also highlights the fact that, without correction, the 
disease burden of infectious diseases will clearly be underestimated. These corrections need to 
be considered very carefully, because in comparison to other input parameters they are the 
major drivers of disease burden. Furthermore, it was aimed to have sex and age-specific MF 
to account for the inherent differences. The process of literature review however, showed that 
such detailed information is widely lacking and sometimes only available for selected 
pathogens, countries or time frames. These aspects have and will further stimulate debate 
about what national surveillance systems capture and what they do not, as well as strategies to 
tackle these shortcomings. 
This thesis has also shown that the assumptions a modeler makes have a substantial impact on 
the resulting calculations of disease burden. This raises the issue of transparency when 
dealing with BoD analyses. The review by Polinder et al. showed that, even though BoD 
studies in general rely on the methods and constructs provided by the GBD study, they vary 
regarding their social value choices or do not report their choices adequately [132]. This in 
consequence limits the comparability of results and it is not clear whether the differences 
between estimates relate to truly observed variance in population health or are simply driven 
by the arbitrary choices of the modeler. This thesis highlighted the fact that the use of age-
weighting and discounting strongly influences the disease burden estimates and, more 
importantly, selectively impacts on different disease groups and single-disease entities. It was 
estimated that for the SEYLLs in Hong Kong the implementation of both concepts would 
result in an overall decrease in SEYLLs of 51.6% and would have a higher impact on group 
one conditions. Time-discounting alone diminished the overall burden by 25.5% with greater 
impact on injuries (group three), reduced by 39.8%. Age-weighting alleviated the overall 
SEYLLs by 33.7% with the larges reductions, of 38.0%, estimated for group one conditions 
[33]. Another important choice when estimating a health-gap measure is the selection of the 
normative health goal. In general, if comparisons across countries are intended, the use of a 
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standard life table as proposed by the GBD approach is appropriate and the review by 
Polinder et al. indicated that most of the included studies used life expectancy values obtained 
from the Standard West Level 25 or 26 life tables [132]. Using a global standard ensures 
comparability across countries, but setting specific choices (e.g. nationally observed life 
expectancies) can result in more sensitive estimates of burden of disease and can provide a 
more accurate overview of population health. This thesis used scenario analyses to estimate 
the impact of altering the standard life expectancy values to those observed in a) Hong Kong 
[33] and b) Germany [30]. The effects of changing the life expectancy are generally smaller 
than those observed for time-discounting and age-weighting but again had a selective impact 
on different disease entities. The SEYLLs as calculated for Hong Kong increased by 10.8% 
with the biggest increases estimated for group one conditions, of 13.5%. In addition to 
condition-specific differences sex-specific differences were also identified. For instance, 
SEYLLs due to group one conditions rose by 18.6% for women and only 9.4% for men, as 
compared to the baseline scenario in Hong Kong. Furthermore, an impact on the disease 
ranking could also be identified and the leading cause of death was no longer “trachea, 
bronchus and lung cancers” but “ischemic heart disease” [33]. These estimates for the four 
selected pathogens in Germany confirm the condition-specific impact. The estimates showed 
a varying impact from a decrease in DALYs of -1.1% for infections with hepatitis B virus to 
an increase of 8% for infections with influenza virus. DALYs due to salmonella spp. 
increased moderately by 5.7% whereas DALYs due to infections with measles virus remained 
relatively stable with a marginal increase of 0.4%. [30]. Thus, it can be concluded that social 
value choices are an important and very sensitive input to SMPH and it should be strongly 
recommended that the publication of BoD estimates should always be accompanied by a 
detailed description of the model specification, data inputs, and the selected value choices. 
The thesis also highlighted the urgent need for sub-national estimates because comprehensive 
and comparable estimates of disease burden are not only important at a national level but can 
also help to identify differences in health patterns within countries. Sub-national estimates are 
generally lacking and are of value especially for countries such as China or Germany, which 
were selected for testing the SEYLL methodology at a sub-national level in countries with a 
well-functioning vital registration system and increased availability of health data. China 
shows significant regional differences in disease patterns ranging from patterns as seen in 
developed countries (in rural areas) to patterns showing the health status of a developed 
country with a high share of e.g. chronic diseases (urban areas) [133]. Therefore, estimating a 
national average as was done in the GBD assessments is of only limited sensitivity and, thus, 
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also of limited use for setting priorities and introducing setting-specific prevention and 
intervention measures. This is also the case for the Special Administrative Unit of Hong 
Kong. Hong Kong shows a premature disease burden pattern that is comparable to other high-
income areas. However, lower respiratory infections generally cause a higher burden than in 
other high-income areas [32, 33, 91, 92]. The data also show a high burden for “trachea, 
bronchus and lung cancers”, denoting smoking as one public health problem for Hong Kong 
and indicating a need for increased spending on e.g. anti-smoking campaigns. In Germany, a 
high-income country, the burden of premature death patterns is dominated by chronic 
conditions; infectious diseases, at least for the premature death patterns, do not play an 
important role. In the case of Germany, it is necessary to go beyond differences in premature 
death patterns arising from epidemiological patterns, and to consider differences in the disease 
burden related to social determinants. Even though Germany in general is a high-income 
country, it faces variously faceted socioeconomic inequalities (e.g. income) which in turn may 
result in health inequalities [134]. The estimates for NRW highlighted “ischemic heart 
disease” as the leading cause of SEYLL which is in agreement with other assessments of 
SEYLL in high-income countries [91-93]. Unfortunately, the estimates for NRW cannot be 
compared to the SEYLLs for other federal states because this is the first assessment of 
premature mortality for Germany, indicating the urgent need for further assessments. This 
also holds for the estimates in Hong Kong. Nevertheless, both studies indicated that using the 
SEYLL as a measure of premature mortality is generally feasible. Both studies highlighted the 
advantage of the SEYLLs over standard mortality statistics that only count the numbers of 
death and do not consider the age at death. To measure the effect of premature mortality, 
time-based measures counting the years of life lost are more appropriate. 
Overall, this thesis has shown that despite the success of the BoD approach, setting specific 
adjustments and sub-national assessments of the disease burden will provide sound additional 
information to currently available health statistics. 
8. Conclusions and implications for public health 
The ongoing efforts of public health to inform decisions about the spending of resources with 
sound evidence are crucial. However, the use of SMPH as shown in this thesis raised several 
challenges that need to be considered when applying SMPH. Combining epidemiological 
surrogate measures of health into a single metric is generally preferable to the use of single 
measures. Nonetheless, one must be aware that even though SMPH such the DALY, or at 
least the general meaning of a lost year of healthy life, is easy to understand and to 
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communicate, the interpretation of these kinds of estimates can be very misleading without 
transparent information about all the input data that informed the calculations. SMPH often 
have a blackbox reputation because not all assessments of BoD provide information about all 
the epidemiological data or assumptions about social value choices [84, 132]. This can result 
in biased information about the health status of a population and in extreme cases lead to 
biased priorities. Keeping the history of the DALY in mind the GBD study presented the 
global health status for the first time and included an impressive number of widely 
heterogeneous health conditions. However, most of the estimates do not currently provide 
information about sub-national health patterns. It is therefore important to stress the need for 
such estimates, because ill health, at least in most countries in the world, is not distributed 
equally across populations. It differs by location, social status, culture and many other 
determinants that impact on health. Public health can profit from such assessments, which 
identify the specific needs of those populations and can tailor strategies to improve their 
health status. According to the objectives of the GBD study, the framework had the aim of 
accommodating a large set of conditions within a single framework using the DALY as the 
main outcome measure. This standardized approach might have a selective impact on 
conditions, as it might not take into consideration the specific aspects of individual diseases. 
Due to their flexibility, the burden of disease framework and the DALY measure itself have 
the potential to be adjusted to specific settings. This has already been shown for many specific 
disease groups [117, 135-137]. Especially for infectious diseases, the pathogen- and 
incidence-based DALY approach seems to be promising, because it takes into account the 
specific characteristics of infectious diseases and is able to capture their comprehensive 
impact. It also allows effects of interventions to be taken into account and can serve as a tool 
for predictions of future disease burden. Estimating the disease burden in terms of DALYs 
can additionally serve as the first step for including monetary aspects and conduct cost of 
illness and cost-effectiveness analyses [109, 138]. 
This thesis highlighted the value of population health measures, especially for the continuous 
monitoring of population health. With a standardized framework, it is possible to track 
changes in population and identify the major drivers of ill health. SMPH are a valuable tool 
for public health to present the health status of populations, but they also help to identify gaps 
in the data and can raise debate about the quality of the available data. When using SMPH one 
must always keep in mind that at the end of the day the BoD estimates are only as strong and 
reliable as the data input. With the use of SMPH, public health can foster debate about the 
availability and quality of health data to ensure continuous improvements. 
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10. Figures and Tables 
 
Box 1: Technical details of the DALY metric 
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YLLs are calculated by multiplying the number of deaths (N) observed for a condition (i) 
at a certain age (a) and according to the sex (s) by the remaining life expectancy (RLE) at 
age of death (ã), which can be estimated from the standard life table (formula 1). 
The incidence-based YLDs are calculated by multiplying the number of incident cases (I) 
by the duration (d) of the condition (i) and the relevant disability weight (dw) (formula 2). 
The prevalence based YLDs are calculated by multiplying the number of prevalent cases 
(P) of a condition (i) by the disability weight (dw) (formula 3). 
As both complementary sub-measures are quantified in years, the sum of these quantities 
equals the DALY (see formula 4) 
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Figure 1: A simplified theoretical framework of population health [37] 
 
 
 
Figure 2: Conceptual framework describing the two basic SMPH families [18] 
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Figure 3: Generic representation of an outcome tree
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Figure 4: Average DALYs, YLDs per year by sex and age group (Error-bars indicate 95% UIs) (adapted 
from [30] ) 
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Baseline scenario (0,0): standard SEYLL without time-discounting and uniform age-weighting 
Scenario 1 (3,1): 3% time-discounting and non-uniform age weights 
Scenario 2 (3,0): 3% time-discounting and uniform age-weights 
Scenario 3 (0,1): no time-discounting and non-uniform age weights 
Figure 5: Scenario analysis with different assumptions about age-weighting and time-discounting [33] 
 
 
Figure 6: Temporal distribution of disease burden after infection with hepatit is B virus [31]
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Figure 7: Comparison of the disease burden for the four selected pathogens (error bars indicate 95% 
UI) (adapted from [30] )
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Table 1: Results overview of disease burden for the selected pathogens expressed in average YLD, YLL, 
DALY with 95% UI [30] 
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